Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR -mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
Yi Zhao,Ying He,Wei Wang,Qi Cai,Fan Ge,Zisheng Chen,Jianqi Zheng,Yuan Zhang,Hongsheng Deng,Ying Chen,Shen Lao,Hengrui Liang,Wenhua Liang,Jianxing He
DOI: https://doi.org/10.1016/s1470-2045(24)00379-6
IF: 54.433
2024-08-19
The Lancet Oncology
Abstract:Summary Background The clinical benefits of immune checkpoint inhibitor (ICI)-based treatments in treating individuals with advanced EGFR -mutated non-small-cell lung cancer (NSCLC) who have progressed on EGFR tyrosine-kinase inhibitors (TKIs) remain controversial. We aimed to review the literature to comprehensively investigate the individual and comparative clinical outcomes of various ICI-based treatment strategies in this population. Methods In this systematic review and meta-analysis, we used single-arm, pairwise, and network meta-analytical approaches. We searched PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov , and relevant international conference proceedings from database inception to Jan 31, 2024, without language restrictions, to identify eligible clinical trials that assessed ICI-based treatments for individuals with advanced EGFR -mutated NSCLC who progressed on EGFR-TKIs. Studies considered eligible were published and unpublished phase 1, 2, or 3 clinical trials enrolling participants with histologically or cytologically confirmed advanced EGFR -mutated NSCLC who had progressed after at least one EGFR-TKI treatment, and that evaluated ICI-based treatment strategies on at least one of the clinical outcomes of interest. The primary outcome analysed was progression-free survival. The protocol is registered with PROSPERO, CRD42021292626. Findings 17 single-arm trials and 15 randomised controlled trials, involving 2886 participants and seven ICI-based treatment strategies (ICI monotherapy, ICI plus chemotherapy [ICI-chemo], ICI plus antiangiogenesis [ICI-antiangio], ICI plus antiangiogenesis plus chemotherapy [ICI-antiangio-chemo], dual ICIs [ICI-ICI], dual ICIs plus chemotherapy [ICI-ICI-chemo], and ICI plus EGFR-TKI [ICI-TKI]), were included. Three of these strategies—ICI monotherapy, ICI-antiangio-chemo, and ICI-chemo—had sufficient data across the included studies to perform a pairwise meta-analysis. The pairwise meta-analysis showed that, compared with chemotherapy, ICI monotherapy led to shorter progression-free survival (hazard ratio [HR] 1·73 [95% CI 1·30−2·29], I 2 =0%), whereas ICI-antiangio-chemo (HR 0·54 [0·44−0·67], I 2 =0%) and ICI-chemo (HR 0·77 [0·67−0·88], I 2 =0%) prolonged progression-free survival. The network meta-analysis showed that ICI-antiangio-chemo yielded the best progression-free survival results, with substantial benefits over ICI-chemo (HR 0·71 [95% credible interval 0·59−0·85]), ICI monotherapy (HR 0·30 [0·22−0·41]), and non-ICI treatment strategies including antiangio-chemo (HR 0·76 [0·58−1·00]) and chemotherapy alone (HR 0·54 [0·45−0·64]). ICI-antiangio-chemo was associated with higher risks of both any-grade and grade 3 or worse adverse events over ICI-chemo and chemotherapy in the network meta-analysis. Interpretation For individuals with advanced EGFR -mutated NSCLC who progressed on EGFR-TKIs, ICI-antiangio-chemo was identified as the optimal treatment option. The toxicity of this treatment was acceptable but needs careful attention. ICI-chemo showed appreciably greater efficacy than the standard-of-care chemotherapy. These findings clarified the roles of ICI-based treatment strategies in this difficult-to-treat refractory population, potentially complementing recent guidelines. Funding None.
oncology